Health is our mission

Areas of Interest

We are actively seeking to expand our pipeline and product portfolio based on the following criteria:

 


License-in (originals)

Women’s Health

Territory: European Union (EU), Russia and Commonwealth of Independent States (CIS), China, Latin-America, Australia 
We are searching for:clinical phase projects with at least an efficacy signal, registered or marketed products
We offer:co-development and co-financing, registration, participation in P&R approval, sales and marketing


 Central Nervous System

Territory: Global
We are searching for: research phase projects for treatment of general negative symptoms (e.g. schizophrenia negative symptoms, bipolar and major depression), treatment of psychotic symptoms (e.g. bipolar disorder) and treatment of cognitive symptoms (e.g. CIAS)
We offer: acquisition of early developments, co-development and co-financing, registration, participation in P&R approval, sales and marketing

        
Other therapy areas (Cardiovascular, Rheumatology, Respiratory, Anti-infectives, CNS late phase), OTC products

Territory: Central and Eastern Europe (CEE), Russia and Commonwealth of Independent States (CIS), China
We are searching for: late-stage clinical phase projects, registered or marketed products
We offer: co-financing, registration, participation in P&R approval, sales and marketing

 

Joint development

We offer early Research and Development collaborations targeting the symptomatic treatment of general negative, psychotic and cognitive symptoms of psychiatric disorders and participation in the design and running of clinical trials in strategically selected areas within the Central Nervous System and Gynecology.


Technology transfer & manufacturing

With the ability to manufacture a broad range of finished dosage forms in state of the art EMA and FDA approved facilities in Hungary, Poland, Romania, Russia and Germany Richter is open to discuss manufacturing opportunities of innovative license-in projects. Richter is also actively searching for contract manufacturing opportunities for his state-of-the-art manufacturing facilities with a special emphasis on contract development and manufacturing of steroid APIs and finished dosage forms.